&w=3840&q=100)
Novo Nordisk to launch weight-loss drug Wegovy in India ahead of schedule
Novo Nordisk is preparing to introduce its blockbuster weight-loss medication, Wegovy, in India earlier than initially planned, according to a report by Moneycontrol. Originally slated for a 2026 launch, the Danish pharmaceutical company is now aiming for an earlier release to capitalise on the growing demand for obesity treatments in the country.
The decision to expedite Wegovy's launch comes in the wake of Eli Lilly's recent introduction of its own weight-loss drug, Mounjaro, in the Indian market. Mounjaro's entry has intensified competition, prompting Novo Nordisk to accelerate its plans to maintain a competitive edge.
'As a healthcare company, we acknowledge our responsibility towards our patients by ensuring treatment availability, access and awareness. India faces a growing need for effective obesity treatments, and we are committed to addressing this urgent health challenge by expanding access to transformative therapies,' the company told Moneycontrol in an email statement.
According to media reports, the impending expiration of semaglutide's patent in India by 2026 has spurred several Indian pharmaceutical companies to develop generic versions of the drug. Companies such as Sun Pharmaceutical, Cipla, Dr Reddy's Laboratories, and Biocon are actively working on their own formulations to tap into the burgeoning weight-loss drug market, projected to reach $100 billion globally by the end of the decade.
Eli Lilly's Tirzepatide drug called Mounjaro –
Weekly injection for type 2 diabetes
Cost: ₹3,500 (2.5 mg), ₹4,375 (5 mg)
Novo Nordisk's Semaglutide drug Rybelsus –
Daily oral medication
Cost: ₹12,000–₹13,000/month
What is Wegovy and how does it help with weight management?
Wegovy is a weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist drug. It contains the active ingredient semaglutide and aids weight loss by suppressing appetite and slowing the digestion process, helping individuals feel fuller for longer. However, it is important to note that some studies have found that many people using GLP-1 weight-loss drugs like Ozempic, Wegovy or Mounjaro regain the weight within months after stopping. For more health updates, follow #HealthWithBS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Happiness curriculum in govt schools makes way for ‘Science of Living'
New Delhi: From Aug, classrooms in Delhi's govt schools will begin to feel very different. Children will learn not just equations and grammar but also how to breathe mindfully, take care of elders and disconnect from their screens. With the introduction of the new Science of Living curriculum, schools are set for a major shift in both spirit and structure. The curriculum, which educators say replaces Happiness curriculum programme introduced by the previous AAP govt, aligns with National Education Policy (NEP) 2020. It was allocated Rs 1.5 crore in Delhi govt's budget. Rooted in ancient Indian knowledge systems, the curriculum integrates concepts like panch kosha (the five layers of human existence) and panch tantra with contemporary life skills. Students will engage in yoga, meditation and mindfulness practices, alongside lessons on emotional well-being, digital detox, moral values and caring for the elderly. While some educators believe it builds upon the foundations of Happiness curriculum, officials describe it as a more holistic evolution. A principal said, "Happiness curriculum focused on nurturing emotional well-being, mindfulness and self-awareness among students through activities like meditation, storytelling and reflective conversations. Science of Living aims to offer a holistic life skills education grounded in scientific, ethical and philosophical principles. " The principal added, "The focus will shift from just emotional wellness to developing a balanced personality equipped with values, discipline, emotional intelligence, decision-making and resilience." The focus spans a wide spectrum of teachings. "The curriculum will also introduce lessons on emotional resilience and the importance of digital detox—both highly pertinent in an age where technology often overwhelms personal space and well-being," an official said. Emotional intelligence is at the heart of this initiative, with the aim to teach students how to understand their own emotions, navigate the complexities of relationships and develop a healthy, balanced outlook on life. It also stresses the importance of resilience in the face of life's inevitable ups and downs, a skill set that is often overlooked in traditional education systems. The programme will incorporate real-world engagement, encouraging students to actively participate in initiatives such as the Yamuna cleaning campaign. It will use a range of creative tools, including field visits, puppet theatre and documentary screenings. Students will also be introduced to socially relevant themes like gender equity and respect for womanhood. Each one-hour session will be conducted twice a month, with a 15-day gap between them. One of the underlying principles is to encourage a reconnection with traditional knowledge. "By engaging with these ancient teachings, students are not only learning history but also applying its wisdom in their daily lives. This approach is perfectly aligned with the goals of NEP 2020, which advocates an education system that nurtures well-rounded individuals who can think critically and contribute meaningfully to society," the official said. What sets this programme apart is its emphasis on experiential learning. Students will participate in activities that are designed to make them live the lessons. "The vision is to help students evolve into emotionally intelligent, self-aware individuals who are equipped with the skills to lead fulfilling and balanced lives," the official said.
Mint
an hour ago
- Mint
DGCA surprise audit finds 4 violations in Turkish Airlines operations, including dangerous goods handling lapses
The Directorate General of Civil Aviation (DGCA) carried out surprise Safety Oversight and Ramp (SOFA/RAMP) inspections of Turkish Airlines' passenger and cargo flights at four major Indian airports — Delhi, Hyderabad, Chennai, and Bengaluru — between 29 May and 2 June 2025. The inspections were conducted under Article 16 of the Convention on International Civil Aviation (ICAO) to assess compliance with international safety standards and DGCA regulations. Following the inspections, the DGCA has directed Turkish Airlines to ensure full adherence to ICAO Standards and Recommended Practices as well as Indian civil aviation rules. The regulator warned that follow-up inspections will be conducted to verify ongoing compliance and urged the airline to promptly address the identified shortcomings. Marshaller competency: At Bengaluru airport, the marshaller responsible for ground operations lacked proper authorisation and did not possess a valid competency card for marshalling functions, raising concerns about safe aircraft guidance on the apron. Aircraft maintenance: During the arrival of an aircraft, a licensed Aircraft Maintenance Engineer (AME) was absent, and a technician performed the required arrival procedures instead. M/s Airworks is the authorised engineering service provider for Turkish Airlines. Dangerous goods handling: Cargo was found to contain dangerous goods requiring explicit DGCA permission for carriage of explosives to, from, or over Indian territory. However, the necessary permission documentation was neither attached nor mentioned in the Dangerous Goods Declaration. Ground handling agreement and equipment accountability: No formal Service Level Agreement (SLA) existed between Turkish Airlines and its Ground Handling Agent (GHA) at Hyderabad and Bengaluru. Ground support equipment such as ladders, step ladders, trolleys, and Ground Power Units (GPUs) lacked proper accountability and monitoring. Globe Ground India was providing ground services without a formal handover from the previous provider, Çelebi. The DGCA has instructed Turkish Airlines to rectify these issues immediately to maintain the highest safety standards. Failure to comply could result in regulatory action, including restrictions on operations.
Time of India
2 hours ago
- Time of India
Hyderabad cardiologist gets US patent for multi-functional cardiac occluder
File photo: Dr Nageswara Rao Koneti HYDERABAD: An innovative device that can fix various types of cardiac defects, designed by Hyderabad-based Dr Nageswara Rao Koneti, who heads the Cardiology Division at Rainbow Children's Heart Institute, has been granted a US patent. Called KONAR-MF Occluder, the multi-functional device can close septal defects in children and adults. It is a double umbrella disc device made of nitinol, a biocompatible nickel and titanium alloy, and is stretchable up to 15 mm. It can treat various conditions, including ventricular septal defects, coronary arteriovenous fistulas, and paravalvular leaks. The device has already been patented in India, Europe (European Commission), Euro-African countries, and South Korea. The multifunctional device not only fixes multiple types of cardiac lesions but also makes advanced cardiac care more affordable for patients in India, as it costs just Rs 50,000 in India compared to Rs 1.2 lakh in Pakistan and Rs 2.5–6 lakhs in other parts of Asia and Europe, said Dr Koneti. Terming this as a proud moment for Indian science, Dr Koneti said: "This US patent validates that innovations from India can meet global standards. It took us over six years to develop the device, and we applied for CE approval in 2018.' He said the US patent now paves the way for a US FDA (US Food and Drug Administration) approval for the device, which has already been implanted in about 10-15 patients in the US on compassionate grounds. "But we can also do clinical trials in the US if required," said Dr Koneti, who is a paediatric interventional cardiologist. He pointed out that the device has already demonstrated its safety and efficacy through over 20 peer-reviewed studies, and over 10,000 of these devices have already been implanted in patients in over 90 countries across Asia, Europe, Latin America, and Africa since the device got CE approval in 2018. The device is manufactured by LifeTech Scientific of China. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
